Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Schizophrenia

  Free Subscription


Articles published in Neuropsychopharmacology

Retrieve available abstracts of 45 articles:
HTML format
Text format



Single Articles


    January 2018
  1. YOUNG JW, Light GA
    Cross-Species Neurophysiological Biomarkers of Attentional Dysfunction in Schizophrenia: Bridging the Translational Gap.
    Neuropsychopharmacology. 2018;43:230-231.
    PubMed     Text format    


    December 2017
  2. DOYLE GA, Berrettini WH
    Failure to Replicate an Association of a LINE-1 Element in ERI1 Exoribonuclease Family Member 3 (ERI3) with Schizophrenia.
    Neuropsychopharmacology. 2017;42:2471.
    PubMed     Text format    


    November 2017
  3. PERKINS KA, Chengappa KR, Karelitz JL, Boldry MC, et al
    Initial Cross-Over Test of a Positive Allosteric Modulator of Alpha-7 Nicotinic Receptors to Aid Cessation in Smokers with or Without Schizophrenia.
    Neuropsychopharmacology. 2017 Nov 29. pii: npp2017292. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  4. SWERDLOW NR, Bhakta SG, Talledo JA, Franz DM, et al
    Effects of Amphetamine on Sensorimotor Gating and Neurocognition in Antipsychotic-Medicated Schizophrenia Patients.
    Neuropsychopharmacology. 2017 Nov 20. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  5. NAGELS A, Cabanis M, Oppel A, Kirner-Veselinovic A, et al
    S-Ketamine-Induced NMDA Receptor Blockade During Natural Speech Production and its Implications for Formal Thought Disorder in Schizophrenia: A Pharmaco-fMRI Study.
    Neuropsychopharmacology. 2017 Nov 6. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  6. STEFANIK L, Erdman L, Ameis SH, Foussias G, et al
    Brain-Behavior Participant Similarity Networks Among Youth and Emerging Adults with Schizophrenia Spectrum, Autism Spectrum, or Bipolar Disorder and Matched Controls.
    Neuropsychopharmacology. 2017 Nov 6. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  7. GIRGIS RR, Ciarleglio A, Choo T, Haynes G, et al
    A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Tocilizumab, an Interleukin-6 Receptor Antibody, for Residual Symptoms in Schizophrenia.
    Neuropsychopharmacology. 2017 Nov 1. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


    September 2017
  8. SMUCNY J, Lesh TA, Newton K, Niendam T, et al
    Levels of Cognitive Control: A Functional Magnetic Resonance Imaging-Based Test of an RDoC Domain Across Bipolar Disorder and Schizophrenia.
    Neuropsychopharmacology. 2017 Sep 26. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  9. RAMSAY IS, Fryer S, Boos A, Roach BJ, et al
    Response to Targeted Cognitive Training Correlates with Change in Thalamic Volume in a Randomized Trial for Early Schizophrenia.
    Neuropsychopharmacology. 2017 Sep 12. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


    August 2017
  10. KEM WR, Olincy A, Johnson L, Harris J, et al
    Pharmacokinetic Limitations on Effects of an Alpha7 Nicotinic Receptor Agonist in Schizophrenia: Randomized Trial with an Extended Release Formulation.
    Neuropsychopharmacology. 2017 Aug 21. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  11. O'DONNELL P
    Microglia Activation in Subjects at Risk for Psychosis, Fact or Fiction?
    Neuropsychopharmacology. 2017 Aug 18. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  12. LEE M, Balla A, Sershen H, Sehatpour P, et al
    Rodent Mismatch Negativity (MMN)/Theta Neuro-Oscillatory Response as a Translational Neurophysiological Biomarker for N-Methyl-D-Aspartate Receptor-Based New Treatment Development in Schizophrenia.
    Neuropsychopharmacology. 2017 Aug 17. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


    July 2017
  13. BRUCATO G, Appelbaum PS, Lieberman JA, Wall MM, et al
    A Longitudinal Study of Violent Behavior in a Psychosis-Risk Cohort.
    Neuropsychopharmacology. 2017 Jul 26. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


    June 2017
  14. COSGROVE D, Mothersill O, Kendall K, Konte B, et al
    Cognitive Characterization of Schizophrenia Risk Variants Involved in Synaptic Transmission: Evidence of CACNA1C's Role in Working Memory.
    Neuropsychopharmacology. 2017 Jun 13. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  15. HAFIZI S, Da Silva T, Gerritsen C, Kiang M, et al
    Imaging Microglial Activation in Individuals at Clinical High Risk for Psychosis: An In-Vivo PET Study with [18F]FEPPA.
    Neuropsychopharmacology. 2017 Jun 12. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  16. DOYLE GA, Crist RC, Karatas ET, Hammond MJ, et al
    Analysis of LINE-1 Elements in DNA from Postmortem Brains of Individuals with Schizophrenia.
    Neuropsychopharmacology. 2017 Jun 6. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


    April 2017
  17. RABIN RA, Barr MS, Goodman MS, Herman Y, et al
    Effects of Extended Cannabis Abstinence on Cognitive Outcomes in Cannabis Dependent Patients with Schizophrenia versus Non-Psychiatric Controls.
    Neuropsychopharmacology. 2017 Apr 26. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  18. LIGHT GA, Zhang W, Joshi YB, Bhakta S, et al
    Single-Dose Memantine Improves Cortical Oscillatory Response Dynamics in Patients with Schizophrenia.
    Neuropsychopharmacology. 2017 Apr 20. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  19. EISENBERG DP, Yankowitz L, Ianni AM, Rubinstein DY, et al
    Presynaptic Dopamine Synthesis Capacity in Schizophrenia and Striatal Blood Flow Change During Antipsychotic Treatment and Medication-Free Conditions.
    Neuropsychopharmacology. 2017 Apr 7. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


    March 2017
  20. SARPAL DK, Robinson DG, Fales C, Lencz T, et al
    Relationship between Duration of Untreated Psychosis and Intrinsic Corticostriatal Connectivity in Patients with Early Phase Schizophrenia.
    Neuropsychopharmacology. 2017 Mar 15. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  21. POGORELOV VM, Rodriguiz RM, Cheng J, Huang M, et al
    5-HT2C Agonists Modulate Schizophrenia-Like Behaviors in Mice.
    Neuropsychopharmacology. 2017 Mar 15. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


    February 2017
  22. ZHEUTLIN AB, Jeffries CD, Perkins DO, Chung Y, et al
    The Role of microRNA Expression in Cortical Development During Conversion to Psychosis.
    Neuropsychopharmacology. 2017 Feb 10. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


    January 2017
  23. PEREZ VB, Tarasenko M, Miyakoshi M, Pianka ST, et al
    Mismatch Negativity is a Sensitive and Predictive Biomarker of Perceptual Learning During Auditory Cognitive Training in Schizophrenia.
    Neuropsychopharmacology. 2017 Jan 31. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  24. HO NF, Holt DJ, Cheung M, Iglesias JE, et al
    Progressive Decline in Hippocampal CA1 Volume in Individuals at Ultra-High-Risk for Psychosis Who do not Remit: Findings from the Longitudinal Youth at Risk Study.
    Neuropsychopharmacology. 2017 Jan 12. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


    December 2016
  25. PETIT EI, Michalak Z, Cox R, O'Tuathaigh CM, et al
    Dysregulation of Specialized Delay/Interference-Dependent Working Memory Following Loss of Dysbindin-1A in Schizophrenia-Related Phenotypes.
    Neuropsychopharmacology. 2016 Dec 16. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


  26. YOUNG JW, Bismark AW, Sun Y, Zhang W, et al
    Neurophysiological Characterization of Attentional Performance Dysfunction in Schizophrenia Patients in a Reverse-Translated Task.
    Neuropsychopharmacology. 2016 Dec 5. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


    November 2016
  27. KIM E, Howes OD, Veronese M, Beck K, et al
    Presynaptic Dopamine Capacity in Patients with Treatment Resistant Schizophrenia Taking Clozapine: An [18F]DOPA PET Study.
    Neuropsychopharmacology. 2016 Nov 18. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


    October 2016
  28. GONG Q, Hu X, Pettersson-Yeo W, Xu X, et al
    Network-Level Dysconnectivity in Drug-Naive First Episode Psychosis: Dissociating Trans-Diagnostic and Diagnosis-Specific Alterations.
    Neuropsychopharmacology. 2016 Oct 26. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


    September 2016
  29. MILLER BJ, Goldsmith DR
    Towards an Immunophenotype of Schizophrenia: Progress, Potential Mechanisms, and Future Directions.
    Neuropsychopharmacology. 2016 Sep 22. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


    August 2016
  30. WIJTENBURG SA, Wright SN, Korenic SA, Gaston FE, et al
    Altered Glutamate and Regional Cerebral Blood Flow Levels in Schizophrenia: A 1H-MRS and pCASL Study.
    Neuropsychopharmacology. 2016 Aug 26. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


  31. SCHOONOVER KE, McCollum LA, Roberts RC
    Protein Markers of Neurotransmitter Synthesis and Release in Postmortem Schizophrenia Substantia Nigra.
    Neuropsychopharmacology. 2016 Aug 23. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


    July 2016
  32. DE LEEUW M, Bohlken MM, Mandl RC, Hillegers MH, et al
    Changes in White Matter Organization in Adolescent Offspring of Schizophrenia Patients.
    Neuropsychopharmacology. 2016 Jul 21. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


    June 2016
  33. HAIG G, Wang D, Othman AA, Zhao J, et al
    The alpha7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study.
    Neuropsychopharmacology. 2016 Jun 20. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


  34. PLITMAN E, Patel R, Chung JK, Pipitone J, et al
    Glutamatergic Metabolites, Volume and Cortical Thickness in Antipsychotic-Naive Patients with First-Episode Psychosis: Implications for Excitotoxicity.
    Neuropsychopharmacology. 2016 Jun 8. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


    May 2016
  35. CHIAPPELLI J, Postolache TT, Kochunov P, Rowland LM, et al
    Tryptophan Metabolism and White Matter Integrity in Schizophrenia.
    Neuropsychopharmacology. 2016 May 4. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


    April 2016
  36. ERYILMAZ H, Tanner AS, Ho NF, Nitenson AZ, et al
    Disrupted working Memory Circuitry in Schizophrenia: Disentangling fMRI Markers of Core Pathology Versus other Aspects of Impaired Performance.
    Neuropsychopharmacology. 2016 Apr 22. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


  37. SCHWEHM A, Robinson DG, Gallego JA, Karlsgodt KH, et al
    Age and Sex Effects on White Matter Tracts in Psychosis from Adolescence though Middle Adulthood.
    Neuropsychopharmacology. 2016 Apr 12. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


  38. FRYER SL, Roach BJ, Wiley K, Loewy RL, et al
    Reduced Amplitude of Low-Frequency Brain Oscillations in the Psychosis Risk Syndrome and Early Illness Schizophrenia.
    Neuropsychopharmacology. 2016 Apr 12. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


  39. GOONAWARDENA AV, Heiss J, Glavis-Bloom C, Trube G, et al
    Alterations in High-Frequency Neuronal Oscillations in a Cynomolgus Macaque Test of Sustained Attention Following NMDA Receptor Antagonism.
    Neuropsychopharmacology. 2016;41:1319-28.
    PubMed     Text format     Abstract available


    March 2016
  40. DU Y, Grace AA
    Amygdala Hyperactivity in MAM Model of Schizophrenia is Normalized by Peripubertal Diazepam Administration.
    Neuropsychopharmacology. 2016 Mar 22. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


  41. CASTRO VM, Roberson AM, McCoy TH, Wiste A, et al
    Stratifying Risk for Renal Insufficiency Among Lithium-Treated Patients: An Electronic Health Record Study.
    Neuropsychopharmacology. 2016;41:1138-43.
    PubMed     Text format     Abstract available


    February 2016
  42. ENWRIGHT JF, Sanapala S, Foglio A, Berry R, et al
    Reduced Labeling of Parvalbumin Neurons and Perineuronal Nets in the Dorsolateral Prefrontal Cortex of Subjects with Schizophrenia.
    Neuropsychopharmacology. 2016 Feb 12. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


    January 2016
  43. BALU DT, Li Y, Takagi S, Presti KT, et al
    An mGlu5 Positive Allosteric Modulator Rescues the Neuroplasticity Deficits in a Genetic Model of NMDA Receptor Hypofunction in Schizophrenia.
    Neuropsychopharmacology. 2016 Jan 7. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


  44. WEICKERT CS, Weickert TW
    Hormone modulation improves cognition in schizophrenia.
    Neuropsychopharmacology. 2016;41:384-5.
    PubMed     Text format    


    December 2015
  45. SEGARRA N, Metastasio A, Ziauddeen H, Spencer J, et al
    Abnormal Frontostriatal Activity during Unexpected Reward Receipt in Depression and Schizophrenia: Relationship to Anhedonia.
    Neuropsychopharmacology. 2015 Dec 28. doi: 10.1038/npp.2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Schizophrenia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: